Poster Presentation Opportunity Available for Nation’s Top Researchers in Oncology
NCCN is now accepting original abstracts for consideration to be presented during the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care General Poster Session, March 12-13, 2015, at The Diplomat in Hollywood, Florida.
NCCN welcomes original abstracts from investigators in the general oncology community, and submissions will be accepted from NCCN Member Institutions, academic institutions, teaching and community hospitals, or industry.
Topics may fall into the general areas below:
Clinical oncology research (all phases)
Preclinical oncology research
Best practices in implementation and Use of clinical practice guidelines
Outcomes and Health services research
The NCCN General Poster Session, including submission review, is overseen by the NCCN Oncology Research Program (ORP). The submission deadline for the NCCN General Poster Session Call for Abstracts is Friday, October 31, 2014, at 11:59 pm EDT. First authors can expect to receive notification via e-mail in mid-December 2014.
Abstracts will be evaluated using a peer-review process. Oncology research faculty from NCCN Member Institutions will serve as peer reviewers to approve research to display at the General Poster Session. All approved original abstracts will be published on JNCCN.org. Select abstracts will also be published in print in JNCCN.
The NCCN Annual Conference: Advancing the Standard of Cancer Care attracts more than 1500 registrants from across the United States and the globe, including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the data upon which the NCCN Guidelines are based, and quality initiatives in oncology.
In recognition of NCCN’s 20th Anniversary, NCCN is planning to hold a special live roundtable during the NCCN Annual Conference comprised of NCCN leadership—past and present—as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years; noteworthy historical NCCN accomplishments and events will be discussed, as well as the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
To learn more about the NCCN General Poster Session, visit NCCN.org.
Patient-Friendly Guide Offers Free Step-by-Step Information for People With Soft Tissue Sarcoma
People with various soft tissue sarcoma diagnoses need access to state-of-the-art treatment information in easy-to-understand language. NCCN has published the NCCN Guidelines for Patients: Soft Tissue Sarcoma for people with various soft tissue sarcoma diagnoses, including sarcomas of the limbs, outer trunk, head, and neck; sarcomas of the inner trunk; gastrointestinal stromal tumors; and desmoid tumors.
The NCCN Guidelines for Patients: Soft Tissue Sarcoma, through the support of the NCCN Foundation, is available to view and download free-of-charge at NCCN.org/patients.
“NCCN is pleased to offer the NCCN Guidelines for Patients: Soft Tissue Sarcoma,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “Considering that sarcomas are rare tumor types, the availability of such a valuable patient information resource indeed empowers patients and their caregivers through knowledge, allowing them to work alongside their care teams to make informed treatment decisions.”
The NCCN Guidelines for Patients, patient-friendly translations of the NCCN Guidelines, are designed to provide people with cancer and their caregivers state-of-the-art treatment information in easy-to-understand language.
The NCCN Guidelines are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms that address appropriate management options from initial work-up throughout the course of the disease. The NCCN Guidelines for Patients translate the professional guidelines in a clear, step-by-step manner that people can use as the basis for discussing treatment options with their physicians.
This resource is written according to plain language principles to improve health literacy, and the design and format feature patient-friendly elements such as medical illustrations alongside descriptions of body parts, tests, and treatments. NCCN Guidelines for Patients: Soft Tissue Sarcoma also includes an expansive glossary with definitions of medical terms and acronyms.
NCCN currently offers NCCN Guidelines for Patients for Breast, Colon, Esophageal, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Caring for Adolescents and Young Adults; Chronic Myelogenous Leukemia; Lung Cancer Screening, Malignant Pleural Mesothelioma; Melanoma, Multiple Myeloma; and Soft Tissue Sarcoma. Funding for the library of NCCN Guidelines for Patients is made possible through the NCCN Foundation.
To download the NCCN Guidelines for Patients: Soft Tissue Sarcoma, visit NCCN.org/patients.
Oncology Experts Mark 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer
NCCN has published its 20th annual edition of the NCCN Guidelines for Small Cell Lung Cancer (SCLC). One of the 8 original NCCN Guidelines, the NCCN Guidelines for SCLC was initially published in November 1996.
“There have indeed been major improvements in the NCCN process since 1996,” said Greg Kalemkerian, MD, Professor, Medical Oncology, University of Michigan Comprehensive Cancer Center, and NCCN Guidelines Panel Chair for SCLC. “Such improvements include the integration of a broader discipline representation on the NCCN Guidelines Panels, the availability of more evidence-based studies to support recommendations and choices, and the inclusion of the ‘Principles of’ sections that provide more detailed information of rationale and details of therapeutic regimens.”
Dr. Kalemkerian noted improvements in the treatment of SCLC since 1996, highlighting NCCN Guidelines recommendations such as the demonstration of survival benefit for prophylactic cranial radiation (PCI), raising PCI—a highly controversial procedure—from category 3 in 1996 to its current status as a category 1 recommendation, based on high-quality evidence and uniform consensus. Similarly, the demonstration of a survival benefit for second-line chemotherapy in relapsed SCLC raised subsequent chemotherapy from a category 3 in 1996 to a category 1 recommendation today. Another improvement was the demonstration of a survival benefit for hyperfractioned thoracic radiotherapy in limited-stage SCLC.
Today, NCCN develops and publishes a library of 59 NCCN Guidelines, covering 97% of cancers affecting people in the United States. The NCCN Guidelines are developed and updated through an evidence-based process in which the expert panels integrate comprehensive clinical and scientific data with the judgment of the multidisciplinary panel members and other experts drawn from NCCN Member Institutions. Access to the complete library of NCCN Guidelines is available free-of-charge to clinicians at NCCN.org.
On March 12-14, 2015, the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care will be held at The Diplomat in Hollywood, Florida. In recognition of NCCN’s 20th Anniversary, NCCN is planning to hold a special live roundtable during the NCCN Annual Conference comprised of NCCN leadership—past and present—as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years; noteworthy historical NCCN accomplishments and events will be discussed, as well as the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
To learn more about NCCN, the NCCN Guidelines, and the NCCN 20th Annual Conference, visit NCCN.org.